To the Editor The use of noninvasive ventilation as first-line therapy for immunocompromised patients with acute respiratory failure remains controversial.1,2 Dr Lemiale and colleagues3 reported the largest randomized clinical trial to date (374 immunocompromised patients) with the aim of assessing whether noninvasive ventilation could improve outcomes. No difference was found between patients treated with oxygen therapy alone or with noninvasive ventilation.
Frat J, Coudroy R, Thille AW. Noninvasive Ventilation and Outcomes Among Immunocompromised Patients. JAMA. 2016;315(17):1901-1902. doi:10.1001/jama.2016.0674